Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avila Therapeutics has released positive clinical data of two Phase 1a clinical studies of AVL-292 , a selective inhibitor of Bruton's tyrosine kinase (Btk) for the treatment of cancer and autoimmune diseases.
Subscribe to our email newsletter
The study of AVL-292-001 was a double-blind, placebo-controlled, single ascending dose study in healthy volunteers and in this study AVL-292 demonstrated favorable safety, tolerability and pharmacokinetics.
In addition, the trial used Avila’s unique covalent probe technology to assess the quantitative relationship among dose level, systemic exposure, and occupancy of the target by AVL- 292.
This combination of analyses provides an understanding of AVL-292 action at the molecular level and serves as a rational guide to future clinical development.
Avila CEO Katrine Bosley said over 50 healthy volunteers participated in these two trials, based on these results, they are actively advancing the clinical development of AVL-292, initially for the treatment of B cell cancers, with a Phase 1b study expected to initiate in mid-2011.
AVL-292 is an orally available, covalent drug which selectively and covalently binds to Btk to inactivate and silence its activity.